RLAY vs ABSI
RLAY and ABSI side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | ABSIABSCI CORP |
|---|---|---|
| Market cap | $4.13B | $1.38B |
| P/S | 269.0x | 492.8x |
| Revenue growth (YoY) | 53.4% | -38.2% |
| Earnings growth (YoY) | 18.1% | -11.7% |
| EBIT margin | -1971.6% | -4297.0% |
| ROE | -31.1% | -46.8% |
| ROIC | — | -84.6% |
| 1y total return | +357.0% | +197.2% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RLAY vs ABSI
| Metric | RLAY | ABSI |
|---|---|---|
| End value | $5.5K | $3.7K |
| Total return | -45.0% | -62.8% |
| CAGR | -10.9% | -17.4% |
| Volatility | 77.7% | 97.7% |
| Sharpe | 0.18 | 0.24 |
| Sortino | 0.27 | 0.37 |
| Max drawdown | -94.7% | -96.2% |
Based on 1294 common trading days, 2021-07-22 → 2026-09-16 · risk-free 4.14% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)